Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Cyclophosphamide 12Rituximab 9fludarabine 6Prednisone 5Vinorelbine 4Vincristine 4Epirubicin 4zanubrutinib 3Nivolumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3Drug Therapy 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Thiotepa 2Metformin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Doxorubicin 2Cytarabine 2Bortezomib 2treosulfan 1plerixafor 1pegfilgrastim 1parsaclisib 1obinutuzumab 1nilotinib 1liposomal doxorubicin 1ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × treosulfan × Lymphoid × Clear all
NCT01079013 2016-04-20

Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Sheba Medical Center

Phase 2 Unknown
40 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡